No Data
Earnings Preview: Olin to Report Financial Results Post-market on May 01
Olin Biotechnology (688319.SH): A net loss of 7.0739 million yuan in the first quarter.
On April 25, Glorious Group reported that Olin Biotech (688319.SH) announced its first quarter report for 2025, achieving revenue of 87.4903 million yuan, a year-on-year increase of 23.58%; net income attributable to shareholders of the listed company was -7.0739 million yuan; and EPS was -0.0174 yuan.
Analysts Estimate Olin (OLN) to Report a Decline in Earnings: What to Look Out for
Is It Time To Consider Buying Olin Corporation (NYSE:OLN)?
Olin Bio: The recombinant golden staph vaccine is expected to be mass-produced in 2027. There is still considerable market space for the adsorbed tetanus vaccine | Directly focus on the Shareholder meeting.
① From Olin's 2024 annual performance, both revenue and net income attributable to the parent company have achieved year-on-year growth. The annual sales revenue of the adsorbed tetanus vaccine has exceeded 0.5 billion yuan for the first time; ② A relevant person in charge of the company stated that among the four major "super bacteria" vaccines currently being researched, the recombinant Staphylococcus aureus vaccine will complete the clinical phase III enrollment and is expected to achieve mass production by 2027.
Government Contract Update: $97M Payment to OLIN WINCHESTER LLC
G3636G : is the biz sale good for AMMO, and is it a good entry?
Trytosaveabit OP G3636G : IMO yes it should help them!
Trailside22 : just sold a gun on Gun Broker. have a .50 BMG that didn’t make the reserve price yet. World record of over 3 miles by a Canadian sniper.
Trytosaveabit OP Trailside22 : Nice! How did you wind up with the Afghanistan ( if i remember correctly? ) Record kill .50
Trailside22 Trytosaveabit OP : bought it in an auction. $15K its yours. it is artillery at its finest
View more comments...